Capricor Therapeutics, Inc. (CAPR)
Nasdaq · Healthcare · Biotechnology
$7.78−13.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $452M
- 52-week range
- $2.96 – $40.37
- 52-week change
- +14.60%
- EPS (trailing)
- −$2.45
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$105M
- Diluted EPS
- −$2.26
- Free cash flow
- −$72.7M
From the company’s annual report on SEC EDGAR.
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.
Headquarters: San Diego, United States · 231 employees · capricor.com